Overview

A Phase 2b Clinical Trial to Evaluate Efficacy and Safety of Weekly Doses of TransCon CNP Compared With Placebo in Participants With Achondroplasia Aged 2 to 11 Years of Age

Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to evaluate efficacy and safety of once weekly SC doses of 100 µg CNP/kg compared to placebo on Annualized Growth Velocity after a 52-week randomized treatment period in children aged 2 to 11 years with genetically confirmed Achondroplasia. The double-blind, placebo-controlled treatment period is followed by an Open Label Extension (OLE) period of a 52-week duration.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ascendis Pharma Growth Disorders A/S